Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07296484 · ClinicalTrials.gov registry record · Phase 2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

A Phase 2 study of Type 2 Diabetes and Cortisol Excess, sponsored by Sparrow Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
1,500
Enrollment target
20
Study locations

NCT07296484: Recruiting Phase 2 study of Type 2 Diabetes and Cortisol Excess, sponsored by Sparrow Pharmaceuticals.

NCT07296484 is a Phase 2 study of Type 2 Diabetes and Cortisol Excess that is actively recruiting participants, run by Sparrow Pharmaceuticals. The registered enrollment target is 1,500 participants, below the 3,919-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07296484, a Phase 2 study of Type 2 Diabetes and Cortisol Excess, is actively recruiting participants, sponsored by Sparrow Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
1,500 participants
Enrollment target
20
Study locations

Study Summary

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Primary Outcome

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

Conditions Studied

Type 2 Diabetes Cortisol Excess

Interventions

  • DRUG Placebo
  • DRUG clofutriben

Study Locations (20)

California

  • Ark Clinical Research - Fountain Valley - Fountain Valley
  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Velocity Clinical Research - Gardena - La Mesa
  • Ark Clinical Research - Long Beach - Long Beach
  • Los Angeles Institute for Metabolic Research - Los Angeles
  • Velocity Clinical Research, Los Angeles - Los Angeles
  • Amicis Research Center- Nordhoff - Northridge

Florida

  • Velocity Clinical Research, New Smyrna Beach - Edgewater
  • The Center for Diabetes and Endocrine Care - Fort Lauderdale
  • Admed Research LLC - Miami
  • Progressive Medical Research - Port Orange

Louisiana

  • Velocity Clinical Research, Lafayette - Lafayette
  • NOLA Care Clinical Research - Metairie
  • Tulane University School of Medicine - New Orleans

Arizona

  • Arizona Clinical Trials - Pecos - Chandler
  • Arizona Clinical Trials - Broadway - Tucson

Iowa

  • Velocity Clinical Research, Sioux City - Sioux City
  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Georgia

  • IACT Health-Brookstone Centre Pkwy - Columbus

Illinois

  • Chicago Clinical Research Institute - Chicago

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2025-11-29
Est. Completion 2028-06-30
Phase Phase 2
Sparrow Pharmaceuticals

6 total trials

What NCT07296484 shows while recruiting

NCT07296484 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 3,919-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (62% lower).

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07296484 names 20 study sites across 7 states, led by California, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT07296484 about?

NCT07296484 is a clinical study titled "Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)". CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the...

What is the current status of trial NCT07296484?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2025-11-29. Estimated completion is 2028-06-30.

What conditions does trial NCT07296484 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Cortisol Excess.

What interventions are being tested in trial NCT07296484?

The interventions under investigation include: Placebo (DRUG), clofutriben (DRUG).

Who is sponsoring clinical trial NCT07296484?

This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07296484 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07296484's enrollment target sits among peer trials

1,500 18th of 327 higher than 310 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00178724 · 1,500 participants

    Spinal Cord Injury Registry - North American Clinical Trials Network

  • NCT00951366 · 1,500 participants

    Preterm Lung Patient Registry

  • NCT01050504 · 1,500 participants

    Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  • NCT02071134 · 1,500 participants

    Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07296484

Source: ClinicalTrials.gov NCT07296484, the US trial registry maintained by the National Library of Medicine. NCT07296484 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.